Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., has recently announced that the U.S. Food and Drug Administration (FDA) has accepted their new drug application (NDA) for rivoceranib in combination with camrelizumab as a first-line treatment option for unresectable hepatocellular carcinoma (uHCC). This is great news for patients and healthcare professionals as it provides..